SG

Steven Gillis

Managing Director at ARCH Venture Partners

Seattle, Washington

Investor
VC

Invests in

Stages:

Series B
Series A

Sectors:

Pharmaceuticals
BioTech
Seattle / Portland

Locations:

Seattle, Washington
  • Min Investment:

    $50,000.00
  • Max Investment:

    $150,000,000.00
  • Target Investment:

    $25,000,000.00

Lists including Steven

AH
AL
AS
AD

Based in Seattle

494 people

AT
AS
AT
AH

All Series A Investors

14748 people

Investments

EGenesis

Series A

Total Funding: $450M

Vilya

Series A

Total Funding: $71M

Proniras

Series B

Total Funding: $5M

Basking Biosciences

Series A

Total Funding: $55M

TFC Therapeutics

Pre Seed

Total Funding:

Bitterroot Bio

Series A

Total Funding: $150M

SonoThera

Series A

Total Funding: $61M

Carrick Therapeutics

Series A

Total Funding: $160M

Pheast Therapeutics

Series A

Total Funding: $76M

Be Biopharma

Series B

Total Funding: $180M

hC Bioscience

Series A

Total Funding: $24M

Mozart Therapeutics

Series A

Total Funding: $55M

HiberCell

Series A

Total Funding: $130M

Walden Biosciences

Series A

Total Funding: $51M

Faraday Pharmaceuticals

Series B

Total Funding: $25M

ImmusanT

Series C

Total Funding: $40M

VBI Vaccines

Series A

Total Funding: $160M

Pulmatrix

Series B

Total Funding: $58M

VentiRx Pharmaceuticals

Series A

Total Funding: $180M

Theraclone Sciences

Series A

Total Funding: $46M

Bluebird Bio

Series C

Total Funding: $130M

Allozyne

Series A

Total Funding: $34M

Work Experience

AV
ARCH Venture Partners

  • Managing Director

Latest Articles

Medium•Aug. 2021

Hallucination or Product Vision?

Defi
Blockchain
Startup
Insurance
decentralized insurance

All information is sourced from public domain and might be inaccurate.

|

By continuing, you're agreeing to our Terms and Privacy Policy.

|

Learn more About The Network.